DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31

Damora Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$19.27+0.83 (+4.50%)

Close on Oct 19, 2026

Market cap: $1.18B
P/E (TTM): 4.8
Dividend yield: 0.00%

Damora Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Stock-Based Compensation	1.00	3.24	5.43	5.57	4.48	0.98	–
Change in Accounts Payable	0.05	-1.33	-1.65	1.82	-1.32	-0.48	1.94
Operating Cash Flow	-6.73	-19	-37	-43	-52	-38	-19
Capital Expenditures	–	–	–	-0.20	-0.22	–	–
Acquisitions	-17	–	–	–	–	–	-0.33
Sale of Property, Plant & Equipment	–	–	0.08	–	–	–	–
Purchase of Investments	–	–	-26	-45	-84	–	–
Sale & Maturity of Investments	–	12	48	57	36	–	–
Investing Cash Flow	-17	12	22	12	-48	–	-0.33
Stock Issued	–	–	2.88	0.51	–	–	–
Financing Cash Flow	267	–	2.88	0.51	–	187	–
Foreign Exchange Rate Adjustments	0.71	-0.32	0.38	0.26	-0.92	3.13	0.05
Free Cash Flow	–	–	–	-43	-53	–	–
Income Taxes Paid	0.01	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -163.8%

Financial strength

Current ratio: 19.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1961.9%

Valuation

P/E ratio: 4.8
Price to sales: –
Price to book: 2.28
Dividend yield: 0.00%